REG-4basebio UK Societas: Annual General Meeting 2021

4BasebioAnnouncement

18/06/2021 07:05

18 June 2021

4basebio UK Societas

("4basebio" or the "Company")

Annual General Meeting 2021 ("AGM")

Following the UK government announcement on 14 June 2021 that lockdown
measures will not be withdrawn by the time of the AGM, the Company confirms
that it intends to hold its 2021 AGM with only the minimum number of
shareholders present as required to form a quorum under the Company's Articles
of Association, and who (being officers or employees of the Company) are
essential for the business of the AGM to be conducted.

As set out in the notice of meeting, the AGM will be held on 30 June 2021 at
9.00am. In view of the continuing risk posed by COVID-19 and having regard to
their own safety and that of others, shareholders and their representatives
are respectfully asked not to seek to attend the AGM in person. To ensure the
safety of the limited number of people whose attendance is essential, we do
not propose to allow other shareholders or their representatives to gain
access to the AGM venue on the day.

In order to ensure shareholders' votes are counted, despite these
restrictions, the Board strongly encourages shareholders to exercise their
right to vote by appointing the chairman of the AGM as their proxy to vote at
the AGM in accordance with their instructions. To appoint a proxy, please
complete the form of proxy and send it to our registrar, Computershare
Investor Services PLC. CREST members who wish to appoint a proxy or proxies
for the AGM (and any adjournment(s) thereof) through the CREST electronic
proxy appointment service may do so by using the procedures described in the
CREST Manual (available via www.euroclear.com). Proxy appointments must be
received by Computershare Investor Services PLC no later than 9:00am on 28
June 2021. If two or more valid forms of proxy are delivered in respect of the
same share, the one which was delivered last (regardless of its date or the
date of its execution) will be valid. Further details are set out in the
notice of meeting and in the form of proxy. 

We, as your Board, are committed to open dialogue with our shareholders and
remain very mindful of ensuring that shareholders have an opportunity to
engage with us. Shareholders are encouraged to submit questions in advance of
the AGM or raise matters of concern as a shareholder by emailing the Company
Secretary using the email address provided in the notice of meeting. Answers
to questions that are of common interest will be published on the Company's
website.  Also, as previously announced, the AGM will be followed by a
presentation from the Company through the Investor Meet Company platform on 1
July 2021 at 10.00am. Investors can sign up to Investor Meet Company for free
and register interest here:
https://www.investormeetcompany.com/4basebio-uk-societas/register-investor

For further enquiries, please contact:

 4basebio UK Societas                                         +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                            
                                                                                  
 Cairn Financial Advisers LLP (Nominated Adviser )            +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                                       
                                                                                  
 finnCap Ltd (Broker)                                                             
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe              +44 (0)20 7220 0500 
                                                                                  
 Walbrook PR                                                  +44 (0)20 7933 8780 
 Anna Dunphy / Paul McManus        Mob: +44 (0)7876 441 001 / +44 (0)7980 541 893 
                                                                                  

Notes to Editors

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for gene therapies and DNA vaccines and providing solutions for effective
and safe delivery of these DNA based products to patients. It is the intention
of the Company to become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological use. The
immediate objectives of 4bb are to validate and scale its DNA synthesis and
advance its collaborations to facilitate the functional validation of its DNA
based products and gene delivery solutions.

The Company divested from 4basebio AG (“4bb AG”), a German company listed
on the Prime Standard segment of the Frankfurt Stock Exchange, following the
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology
business to AIM-quoted Abcam plc in January 2020 for €120million. Following
the disposal, 4bb AG retained its genomics business which owned and licensed
certain intellectual property including its proprietary, patent-protected
technology, TruePrime™. This is the foundation for building the Company’s
synthetic DNA manufacturing business which 4bb AG transferred to the Company
along with funding to continue the Company’s development and investment.



Copyright (c) 2021 PR Newswire Association,LLC. All Rights Reserved